Growth hormone-secreting pituitary adenomas that cause acromegaly arise as monoclonal
expansions of differentiated somatotroph cells and are usually sporadic. They are almost …

Abstract The 11th Acromegaly Consensus Conference in April 2017 was convened to
update recommendations on therapeutic outcomes for patients with acromegaly. Consensus …

Acromegaly is a chronic systemic disease with many complications and is associated with
increased mortality when not adequately treated. Substantial advances in acromegaly …

Objective: The aim was to formulate clinical practice guidelines for acromegaly. Participants:
The Task Force included a chair selected by the Endocrine Society Clinical Guidelines …

Acromegaly is a rare disorder caused by chronic growth hormone (GH) hypersecretion.
While diagnostic and therapeutic methods have advanced, little information exists on trends …

Objective: The Acromegaly Consensus Group met in April 2009 to revisit the guidelines on
criteria for cure as defined in 2000. Participants: Participants included 74 neurosurgeons …

Abstract In March 2013, the Acromegaly Consensus Group met to revise and update
guidelines for the medical treatment of acromegaly. The meeting comprised experts skilled …

In evolutionary terms, GH and intracellular STAT 5 signaling is a very old regulatory system.
Whereas insulin dominates periprandially, GH may be viewed as the primary anabolic …

Dysregulated growth hormone (GH) hypersecretion is usually caused by a GH-secreting
pituitary adenoma and leads to acromegaly—a disorder of disproportionate skeletal, tissue …

" Objective: The Acromegaly Consensus Group reconvened in November 2007 to update
guidelines for acromegaly management. Participants: The meeting participants comprised …